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DecappingLuteinizing hormone receptor undergoes downregulation during preovulatory Luteinizing hormone surge
through a post-transcriptional mechanism involving an RNA binding protein designated as LRBP. The present
study examined the mechanism by which LRBP induces the degradation of Luteinizing hormone receptor
mRNA, speciﬁcally the role of decapping of Luteinizing hormone receptor mRNA and the translocation of
LRBP-bound Luteinizing hormone receptor mRNA to degradative machinery. Immunoprecipitation of the
complex with the 5′cap structure antibody followed by real time PCR analysis showed progressive loss of
capped Luteinizing hormone receptor mRNA during downregulation suggesting that Luteinizing hormone
receptor mRNA undergoes decapping prior to degradation. RNA immunoprecipitation analysis conﬁrmed
dissociation of eukaryotic initiation factor 4E from the cap structure, a step required for decapping.
Furthermore, RNA immunoprecipitation analysis using antibody against the p body marker protein, DCP1A
showed that Luteinizing hormone receptor mRNA was associated with the p bodies, the cytoplasmic foci
that contain RNA degradative enzymes and decapping complex. Immunohistochemical studies using anti-
bodies against LRBP and DCP1A followed by confocal analysis showed colocalization of LRBP with DCP1A dur-
ing downregulation. This was further conﬁrmed by co-immunoprecipitation of LRBP with DCP1A. The
association of LRBP and Luteinizing hormone receptor mRNA in the p bodies during downregulation was fur-
ther conﬁrmed by examining the association of a second p body component, rck/p54, using immunoprecip-
itation and RNA immunoprecipitation respectively. These data suggest that the association of LRBP with
Luteinizing hormone receptor mRNA results in the translocation of the messenger ribonucleoprotein com-
plex to the p bodies leading to decapping and degradation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Luteinizing hormone receptor (LHR) expression undergoes dy-
namic changes during normal ovarian cycle. More remarkable
among these changes is the downregulation of the receptor during
preovulatory LH surge [1–4]. This can also be mimicked in vivo by a
pharmacological dose of its ligands. Previous studies from our labo-
ratory have shown that downregulation of LHR mRNA occurs
through a post-transcriptional mechanism where the mRNA un-
dergoes degradation through its association with an RNA binding
protein, designated as LHRmRNA binding protein (LRBP) [5]. Further
studies showed that the expression of LRBP follows a reciprocal rela-
tionship with LHRmRNA [6]. The RNA binding proteinwas then iden-
tiﬁed as being mevalonate kinase (MVK) [5–7]. In agreement with ourilding I, 1301 Catherine Street,
; fax: +1 734 936 8617.
n).
rights reserved.studies, Ikeda et al. showed that overexpression of MVK abrogated the
FSH-induced increase in LHR mRNA expression in rat granulosa cells
[8] further supporting the notion that LRBP is a negative regulator of
LHR mRNA expression. Furthermore, during downregulation, LRBP
translocates to the ribosomes and binds to the coding region of LHR
mRNA to form an untranslatable complex, which is then targeted for
degradation [9–11].
mRNA is predominantly degraded by processes initiated by shorten-
ing of the poly A tail via deadenylation. The deadenylated mRNA then
undergoes decapping in the p bodies, where the 5′7mGpppN cap is re-
moved. The decapped mRNA is then hydrolyzed by 5′-3′ exonuclease
[12,13]. p bodies, the site of mRNA degradation, are aggregates of RNA
and proteins thatwas found to play an important role in the translation-
al suppression and degradation of mRNAs [14,15]. Since p-body aggre-
gates contain intermediates of mRNA decay, it has been suggested
that they serve as sites of mRNA degradation [14]. They contain
decapping enzymes, DCP1 and DCP2 as well as the mammalian 5′–3′
exonuclease XRN1 [15–20]. Since LHR mRNA undergo accelerated deg-
radation during downregulation, we examined the events that lead to
1174 B. Menon et al. / Biochimica et Biophysica Acta 1833 (2013) 1173–1179the degradative procedures speciﬁcally focusing on the role of p body
components.
In the present study, we show the association of the untranslatable
LRBP–LHRmRNP complexwith speciﬁc p bodymarkers and subsequent
decapping and degradation of LHR mRNA. Thus, the present study un-
ravels the mechanism of accelerated degradation of LHR mRNA during
ligand-induced downregulation by identifying the components in-
volved in the process.
2. Materials and methods
2.1. Materials
Pregnant mare serum gonadotrophin (PMSG) and Anti-2,2,7-
trimethyl guanosinemonoclonal antibody agarose conjugate were pur-
chased from Calbiochem (San Diego, CA). Highly puriﬁed human chori-
onic gonadotrophin (hCG; CR 127) was purchased from Dr. A. F. Parlow
(National Hormone and Peptide Program, Torrance, CA). EDTA-free
protease inhibitor mixture tablets and RNAse inhibitor (rRNasin)
were purchased from Roche Applied Science (Indianapolis, IN) and
Promega (Madison, WI) respectively. Real time PCR primers for LH
receptor and 18S rRNA (TaqMan Assay-on-Demand Gene Expression
Product) as well as Multiscribe reverse transcriptase were from Ap-
plied Biosystems (Foster City, CA). Since LRBP was identiﬁed as
MVK, anti-N-terminal mevalonate kinase IgG was raised against the
ﬁrst 15 N-terminal amino acids of MVK (MLSEVLLVSAPGKVI) and
this antibody is referred to as the LRBP antibody in the text. Puriﬁed
antibodies against β tubulin, DCP1A (Sigma, St. Louis, MO), eIF4E and
rck/p54 (Santa Cruz biotech. Santa Cruz, CA) were commercial prod-
ucts. The Super Signal West Femto chemiluminescence kit and
anti-rabbit/anti mouse IgG conjugated to horseradish peroxidase
were obtained from Pierce (Rockford, IL). BCA reagent was pur-
chased from GE Healthcare Life Sciences (Piscataway, NJ). ProLong
Gold antifade reagent with DAPI, anchored Oligo(dT) primer, oligo-
nucleotides and primers speciﬁc for LH receptor, RNase H as well as
Alexa ﬂuor 594-labeled goat anti-mouse IgG and 488-labeled goat
anti-rabbit IgGs were from Invitrogen (Grand Island, NY).
2.2. Animals and tissues
Superovulation was induced in 23 day old Sprague–Dawley rats by
subcutaneous injection of 50 IU of PMSG followed by 25 IU of hCG
56 h later. The day of hCG injection was taken as 0. LH receptor
downregulation was induced by the injection of 50 IU of hCG on day
5. Ovaries were collected 0, 2, 4 and 6 h after hCG injection and were
frozen in liquid nitrogen until further use.
2.3. Immunoprecipitation (IP)
Ovaries were homogenized in RIPA buffer and the homogenates
were centrifuged at 10,000 ×g for 10 min at 4 °C. Equal amounts of
protein from each sample (S10 fractions) were incubated overnight
in primary antibody against the protein of interest at 4 °C followed
by which they were incubated in Protein A-Agarose beads for 2 h at
4 °C. The immunoprecipitated proteins were then analyzed by
SDS-PAGE and Western blot.
2.4. RNA immunoprecipitation (RIP)
Ovaries were homogenized in NET-2 buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, and 0.05% Nonidet P-40) containing RNasin
(100 units/0.5 ml of buffer) and protease inhibitors. The homogenates
were centrifuged at 10,000 ×g for 10 min at 4 °C. The supernatants
were collected and 1–1.5 mg of protein/ml from the extracts (S10 frac-
tions) was used for immunoprecipitation of RNP complex as described
before [9].2.5. Real-Time PCR (qPCR) analysis
Total RNAs were reverse-transcribed and subjected to real time
PCR quantitation as described before [21]. The fold change in gene
expression was calculated using the ΔΔCt method with 18S rRNA
as the internal control.
2.6. Western blot analysis
For this, tissue homogenates (S10 fractions) in RIPA buffer or immu-
noprecipitates were subjected to 10% SDS-PAGE under reducing condi-
tions followed byWestern blot analysis as previously described [6]. The
presence of immune complexes was detected by chemiluminescence.
2.7. Immunostaining of the ovaries
Parafﬁn sections of the ovaries were hydrated, blocked and incu-
bated with anti-DCP1A and MVK antibodies (dilution 1:25 in PBS
containing 0.1% BSA) at 4 °C overnight. Tissue sections were then
double-stained with Alexa Fluor 594-labeled goat anti-mouse IgG
(dilution 1:100) and Alexa Fluor 488-labeled goat anti-rabbit IgG
(dilution 1:100) at room temperature for 2 h. Sections were
mounted using ProLong Gold antifade reagent with DAPI, observed
using a confocal photomicroscope (Olympus FluoView FV500) and
photographed.
2.8. Statistical analysis
Statistical analysis was carried out using one-way ANOVA followed
by the Tukeymultiple comparison test. Values were considered statisti-
cally signiﬁcant for pb0.05. Each experiment was repeated at least
three times with similar results. Blots and autoradiograms shown are
representative of a minimum of three experiments.
3. Results
3.1. LHR mRNA undergoes decapping prior to downregulation
We examined the role of decapping of LHR mRNA during down-
regulation, since it is believed that decapping precedes 5′–3′ exonucle-
ase mediated mRNA degradation. For this, cytosolic S10 fractions from
control and downregulated ovaries were immunoprecipitated with
7-met guanosine (cap structure) antibody. Total RNA was then isolated
from the immunoprecipitatewhich selectively contains cappedmRNAs.
The amount of capped LHR mRNA present in the immunoprecipitates
was then determined by real time PCR using speciﬁc primers. The re-
sults clearly showed that LHR mRNA undergoes regulated decapping
during downregulation and the extent of decapping increasedwith pro-
gression of downregulation. There was a 20% decrease in the levels of
capped LHR mRNA by 2 h of downregulation (Fig. 1A). The decapping
showed a further increase at 4 and 6 h, when the capped LHR mRNA
in the downregulated samples were reduced to 40% and 25%, respec-
tively of that of the control (Fig. 1A). To further conﬁrm this ﬁnding,
the decreased association of capped LHR mRNA with eukaryotic ini-
tiation factor 4E (eIF4E) was examined. eIF4E, which is a component
of the cytoplasmic cap-binding complex, stabilizes mRNA by binding
to its cap structure [22]. To accomplish this, we performed an
RNA-immunoprecipitation in the cytosolic S10 fractions using
eIF4E antibody. RNA associated with immunoprecipitates was
extracted and the levels of LHR mRNA associated with eIF4E were
then determined using real time PCR. We also conﬁrmed the identity
of eIF4E by performing Western blot analysis of the immunoprecipi-
tates (data not shown). As evident from Fig. 1B, the levels of LHR
mRNA associated with eIF4E were signiﬁcantly reduced in the
downregulated samples when compared to the control. There was
an 80% decrease in the association of LHR mRNA with eIF4E by 4 h
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Fig. 1. LHR mRNA undergoes decapping prior to downregulation. (A) Rats were injected
with hCG on the ﬁfth day of superovulation, ovaries were collected 0, 2, 4 and 6 h later
and cytosolic extracts (S10) prepared. Equal amounts of protein from the control (CTL)
or hCG-treated S10 fractionswere subjected to immunoprecipitation using agarose conju-
gated 7-methyl guanosine antibody followed by real time PCR using predesigned primers
and probes for rat LH receptor mRNA as described in Materials and methods. Total LHR
mRNA levels present in the S10 fractions were also measured using real time PCR. The
graphs represent ratio of LHR mRNA levels in the immunoprecipitate normalized to
total LHR mRNA and are shown as fold change vs. control. Error bars represent mean±
SE. *pb0.05, n=3. (B) Equal amounts of protein from the control (CTL) or hCG-treated
S10 fractions were subjected to RIP using antibodies against eIF4E followed by real time
PCR using predesigned primers and probes for rat LH receptor mRNA as described in
Materials and methods. Total LHR mRNA levels present in the S10 fractions were also
measured using real time PCR. The graphs represent ratio of LHR mRNA levels in the im-
munoprecipitate normalized to total LHRmRNA and are shown as fold change vs. control.
Error bars represent mean±SE. *pb0.05, n=3.
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Fig. 2. Association of LHRmRNAwith p bodymarker DCP1A during downregulation. Rats
were injectedwith hCG on the ﬁfth day of superovulation, ovaries were collected 0, 4 and
6 h later and cytosolic extracts (S10) prepared. Equal amounts of protein from the control
(CTL) or hCG-treated S10 fractions were subjected to immunoprecipitation using DCP1A
antibody followed by real time PCR using predesigned primers and probes for rat LH re-
ceptor mRNA as described in Materials and methods. Total LHR mRNA levels present in
the S10 fractions were also measured using real time PCR. The graphs represent ratio of
LHR mRNA levels in the immunoprecipitate to total LHR mRNA and are shown as fold
change vs. control. Error bars represent mean±SE. *pb0.05, n=4.
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that during downregulation, eIF4E dissociates from the cap structure
that normally stabilizes the complex. Thus, dissociation of eIF4E from
the capped LHR mRNA-LRBP complex facilitated decapping to allow
LHR mRNA degradation to occur.
3.2. Translocation of LHR mRNA to the p bodies during
hCG-induced downregulation
One of the major pathways of mRNA degradation in the eukaryotes
involves decapping followed by 5′–3′ degradation in the p bodies. Since
our results showed that decapping occurs during downregulation, as a
next step we determined if LHR mRNA decay involves translocation of
the untranslatable LHR mRNA–LRBP complex from the ribosomes to
the p bodies. For this, the interaction of LHR mRNA with one of the p
body marker proteins, DCP1A was examined. Immunoprecipitation of
the cytosolic S10 fractions with an antibody against DCP1A, followed
by real time PCR showed that there was a 4-fold increase in the associ-
ation of LHR mRNA with the p body component DCP1A in the 4 h
hCG-treated sample compared to control (Fig. 2). This association was
further increased to 7 fold at 6 h of hCG treatment, showing that theassociation of LHR mRNA with the p body components increases as
downregulation progresses.
3.3. LRBP associates with p body marker, DCP1A during LHR
mRNA downregulation
We hypothesized that the association of LHR mRNA with LRBP might
be necessary for the translocation of LHRmRNA to the p bodies. To verify
this, cytosolic S10 fractions were immunoprecipitated with DCP1A anti-
body and the immunoprecipitates were subjected to Western blot anal-
ysis using LRBP antibody. The results presented in Fig. 3 clearly show
that direct interaction of LRBP with the p body component, DCP1A, oc-
curs during downregulation and this association was found to be in-
creased signiﬁcantly after 4 and 6 h of hCG treatment (Fig. 3A). The
reverse IP experiments using LRBP antibody for immunoprecipitation
and DCP1A antibody for Western blot analysis, also yielded similar re-
sults (data not shown). Thus, the association of LRBP with LHR mRNA
plays a critical role in the transport of LHR mRNA from the ribosomes
to the p bodies for its regulated degradation. To further conﬁrm the asso-
ciation of LRBP with p bodies, immunohistochemistry was performed
using primary antibodies against LRBP and DCP1A followed by confocal
microscopic analysis. The top left panels in Fig. 3B (a, a1 e and e1)
show the Dapi images and the right panels (b, b1, f and f1) show LRBP
staining in green. The bottom left panels (c, c1, g and g1) show DCP1A
staining in red and the bottom right panels (d, d1, h and h1) show the
merged image of LRBP and DCP1A staining. The results showed an in-
crease in LRBP staining during downregulation compared to the control.
There was no signiﬁcant change in the intensity of DCP1A staining be-
tween control and hCG treated samples. However, the data clearly
show that there was a strong association of LRBP with DCP1A as
evident from the merged image of the downregulated sample. The yel-
low stain in the downregulated sample (see arrows in panel h, h1) indi-
cates colocalization of the two proteins, which is not present in the
control (panel d, d1). This result further conﬁrmed our notion that during
hCG-induced downregulation, LRBP mediates the transport of LHR
mRNA to the p bodies for subsequent degradation.
3.4. Association of LHR mRNA and LRBP with the p body component
protein rck/p54 during hCG-induced LHR mRNA downregulation
The association of LHR mRNA and LRBP with the p bodies
during downregulation was further conﬁrmed by examining their
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Fig. 3. Association/colocalization of LRBP with the p body marker during LHR mRNA downregulation. (A) Rats were injected with hCG on the ﬁfth day of superovulation, ovaries
were collected 0, 4 and 6 h later and cytosolic extracts (S10) prepared. Equal amounts of protein from the control (CTL) or hCG-treated S10 fractions were subjected to immuno-
precipitation using DCP1A antibody followed by Western blot analysis using LRBP antibody (upper panel). The membranes were stripped and reprobed for DCP1A (lower panel).
The blots shown are representative of three independent experiments. The graphs represent LRBP levels normalized to DCP1A and are shown as fold change vs. control. Error bars
represent mean±SE. *pb0.05, n=4. [B] Immunoﬂuorescence analysis of control (CTL) and hCG treated (4 h) rat ovaries using confocal microscopy. The frozen ovary sections were
incubated with antibodies against DCP1A and LRBP, followed by corresponding Alexa Fluor dye conjugated secondary antibodies and then ﬁxed in a DAPI containing antifade re-
agent. The images are shown in 60× (top) and 100× (bottom) magniﬁcations. The top panels on each section show DAPI (a,a1 & e, e1; blue ﬂuorescence) on the left and LRBP (b, b1
& f, f1; green ﬂuorescence) on the right. Bottom panels show DCP1A (c, c1 & g, g1; red ﬂuorescence) on the left and merged image on the right (d, d1 & h, h1; yellow stain; one
representative spot is indicated by an arrow in each panel). Experiment was repeated 4 times with same results.
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helicase, DDX6 or DDX6-like proteins such as p54 are known to in-
teract with non-translating mRNA and are present in the p bodies
[23]. To examine the association of LRBP–LHR mRNP complex with
rck/p54, we immunoprecipitated the cytosolic fractions with an anti-
body against rck/p54. The immunoprecipitates were either used for
total RNA isolation followed by real time PCR to analyze the association
of LHRmRNA or subjected toWestern blot analysis to determine the in-
volvement of LRBP. As shown in Fig. 4, therewere 5-fold and 7.5-fold in-
creases in the association of LHR mRNA with rck/p54 in the 4 and 6 hhCG-treated samples, respectively compared to the control, further
conﬁrming the association of LHR mRNA with the p body components
duringdownregulation. Similarly, the results presented in Fig. 5 showed
that the association of LRBP with rck/p54 increased progressively and
signiﬁcantly as downregulation progressed. In order to determine if
there were any changes in the number of p bodies, we also analyzed
the changes in the expression of p body marker proteins during
downregulation. No change in the expression of either of these proteins
was seen during downregulation (Fig. 6). This was conﬁrmed by
the absence of any changes in the size or number of p bodies in
Fig. 4. Association of LHR mRNA with p body component protein rck/p54 during
downregulation. Rats were injected with hCG on the ﬁfth day of superovulation, ova-
ries were collected 0, 4 and 6 h later and cytosolic extracts (S10) prepared. Equal
amounts of protein from the control (CTL) or hCG-treated S10 fractions were subjected
to immunoprecipitation using rck/p54 antibody followed by real time PCR using
predesigned primers and probes for rat LH receptor mRNA as described in Materials
and methods. Total LHR mRNA levels present in the S10 fractions were also measured
using real time PCR. The graphs represent ratio of LHR mRNA levels in the immunopre-
cipitate to total LHR mRNA and are shown as fold change vs. control. Error bars repre-
sent mean±SE. *pb0.05, n=3.
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Fig. 6. Expression of p bodymarkersDCP1A and rck/p54 during LHRmRNAdownregulation.
Rats were injected with hCG on the ﬁfth day of superovulation, ovaries were collected 0, 4
and 6 h later and cytosolic extracts (S10) prepared using RIPA buffer. Equal amounts of pro-
tein from the control (CTL) or hCG-treated S10 fractionswere subjected toWesternblot anal-
ysis using DCP1A antibody (upper panel). The membranes were stripped and reprobed ﬁrst
for rck (middle panel) and ﬁnally for tubulin (lower panel). The blots shown are representa-
tive of three independent experiments. The graphs represent DCP1A and rck levels normal-
ized to tubulin and are shown as fold change vs. control. Error bars represent mean±SE.
*pb0.05, n=4–7.
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change in the pattern of p bodies with or without hCG treatment
(panels d and g). These results suggest that the p body formation occurs
at the onset of downregulation and the quantity of p bodies does not ap-
pear to change during the time course of downregulation.
4. Discussion
Studies employing microarray analyses have revealed that 40–50%
of the changes in gene expression pattern in response to cellular sig-
nals occur at the level of mRNA stability [24,25]. These changes are
usually induced by alterations in the composition of messenger ribo-
nucleoproteins (mRNPs) that either inhibit or facilitate mRNA decay.
A similar mechanism, involving alteration of mRNA stability, is re-
sponsible for the changes in LHR mRNA expression during ovarian
cycle [6,26]. Our past studies revealed a crucial role for an mRNA
binding protein, designated as LRBP, in LHR downregulation duringCTL hCG-4h hCG -6h
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Fig. 5. Association of LRBP with p body component protein rck/p54 during downregulation.
Rats were injected with hCG on the ﬁfth day of superovulation, ovaries were collected 0, 4
and 6 h later and cytosolic extracts (S10) prepared using RIPA buffer. Equal amounts of pro-
tein from the control (CTL) or hCG-treated S10 fractions were subjected to immunoprecipi-
tation using rck/p54 antibody followed byWestern blot analysis using LRBP antibody (upper
panel). The membranes were stripped and reprobed for rck (lower panel). The blots shown
are representative of three independent experiments. The graphs represent LRBP levels nor-
malized to rck and are shown as fold change vs. control. Error bars represent mean±SE.
*pb0.05, n=4.preovulatory LH surge [5,6,26,27]. We have shown that LRBP associ-
ates with LHR mRNA in the ribosomes and the untranslatable com-
plex formed is routed for degradation [9]. Here we show that during
ligand-induced downregulation, LHR mRNA accumulates in the p
bodies, where it undergoes decapping. Using confocal microscopy
and immunoprecipitation experiments, we further show that the
LHR mRNA binding protein, LRBP, also associates with the p bodies
during LHR mRNA downregulation. These results suggest that the
untranslatable mRNP complex consisting of LHR mRNA and LRBP is
translocated from the ribosomes to the p bodies, where it undergoes
decapping making it a potential target for degradation by 5′-3′
exonuclease.
mRNAs are predominantly degraded by two possible pathways in
eukaryotic cells that are initiated by shortening of the poly A tail
(deadenylation). In one pathway, the deadenylated mRNAs undergo
decapping to remove the 5′7mGpppN cap prior to degradation by
5′-3′ exonucleases in the p bodies. In the second pathway,
deadenylated mRNAs are degraded by 5′-3′ exonucleases in the cy-
toplasmic exosomes [12,13]. Since LHR mRNA undergoes decapping
prior to degradation, it points to the strong possibility that LHR
mRNA is degraded by the 5′-3′ exonuclease in the p bodies. This is
consistent with the notion that translationally suppressed mRNAs
accumulate in the p bodies to undergo decapping [28]. p bodies are
dynamic structures that are formed to degrade translationally
suppressed mRNAs [14,15]. Using two different markers of p bodies,
we were able to demonstrate that LHR mRNA associates with p body
components during downregulation. However, the number or size of
the p bodies showed no signiﬁcant changes during downregulation.
This was not surprising since LHR mRNA accounts for only a small
proportion of the total mRNAs in the ovary. Furthermore, stimula-
tion of the cAMP/PKA pathway, in response to LH/hCG treatment, in-
stituted to induce LHR mRNA downregulation, causes the activation
of transcription of a large number of unrelated genes that might
further dilute the relative abundance of LHR mRNA. The results
presented in this study demonstrate that LRBP is also colocalized
with LHRmRNA in the p bodies during downregulation. Thus, during
downregulation, LRBP remains associated with actively translating
LHR mRNA from the outset until it is degraded in the p bodies.
Since LRBP directly binds to both p body marker proteins (DCP1A
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Fig. 7. Proposed mechanism of LH/hCG stimulated and LRBP mediated degradation of LHR mRNA in the p bodies. LH signaling through its receptor activates cAMP/PKA followed by
the ERK pathway, leading to increased levels of LRBP. LRBP binds to the coding region of LHR mRNA in the ribosomes, to form an untranslatable ribonucleoprotein complex. LRBP
also associates with the p body components such as DCP1A and rck/p54 resulting in the p body localization of LRBP–LHR mRNP complex. This is accompanied by the dissociation of
eIF4E from the cap structure. In the next step, LHR mRNA undergoes decapping in the p bodies initiated by the enzyme DCP2. This leads to the 5′–3′ exonuclease (XRN1) mediated
degradation of LHR mRNA, in the ﬁnal step.
1178 B. Menon et al. / Biochimica et Biophysica Acta 1833 (2013) 1173–1179and rck) during downregulation, it is likely that the p bodies might
interact with LHR mRNA that has been bound to LRBP.
There are several other examples where mRNA binding proteins
have been shown to deliver mRNAs to p bodies by interacting with
p body components [29–32]. In particular, the cytoplasmic poly-
adenylation element-binding protein (CPEB-1), an RNA-binding pro-
tein that plays a role in translational control in oocytes and localized
in p bodies, has been shown to interact with a number of p body com-
ponents such as rck/p54 [33]. It is also possible that LRBPmight interact
with other yet unidentiﬁed factors/proteins for transporting the com-
plex to the p bodies. In this context, our previous studies [34] have
shown that LRBP can interact with other proteins such as ubiquitin con-
jugating enzyme 2i (UBCE2i), a SUMO conjugating enzyme and eIF5A, a
ubiquitous protein believed to be involved in translational suppression
and decay in other systems. Thus it is possible that the interaction of
LRBPwith one ormore of these proteinsmight be involved in the trans-
location of LRBP–LHR mRNP complex to the p bodies.
In summary, a model for LRBP-mediated LHR mRNA decay is pro-
posed, which is illustrated in Fig. 7. LH activates cAMP/PKA/ERK path-
way leading to an increase in the expression of LRBP [35,36]. LRBP
binds to the coding region of LHR mRNA in the ribosomes to form an
untranslatable complex [9–11]. LRBP then associates with the p body
components such as DCP1A and rck/p54 thereby inducing the p body
localization of LRBP–LHR mRNP complex. This is accompanied by the
dissociation of eIF4E from the cap structure and decapping. Exposure
of the uncapped, nascent 5′ end of LHRmRNA facilitates its degradationby the 5′–3′ exonuclease, XRN1, culminating in the downregulation of
LHR.
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